KBC Group’s First Tracks Biotherapeutics TRAX Stock Holding History

KBC Group’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$41K	Buy	+1,149	New	+$44.9K	﹤0.01%	1761

Other funds holding TRAX

Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Adirondack Trust Company Saratoga Springs, New York $320M AUM 23.25% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

KBC Group's TRAX Position: Q3 2026 in Review

KBC Group opened a new position in First Tracks Biotherapeutics (TRAX) in Q3 2026: 1,149 shares worth $41K. The stake represents ﹤0.01% of the portfolio and ranks #1761 among its holdings.

12 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.

KBC Group held 1,149 shares of First Tracks Biotherapeutics worth $41K as of Q3 2026.
First Tracks Biotherapeutics was a new KBC Group position in Q3 2026.
First Tracks Biotherapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1761 holding.
12 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.